Reduced-Dose Enfortumab Vedotin, Treatment Continuity, and Survival in Urothelial Cancer
This retrospective cohort study examines the association of upfront treatment with enfortumab vedotin plus pembrolizumab with clinical outcomes for patients with advanced urothelial cancer.
Authors
- Ramy Sedhom (ORCID: https://orcid.org/0000-0001-8937-0726)
- Ryan D. Chow (ORCID: https://orcid.org/0000-0002-1872-6307)
- Ronac Mamtani (ORCID: https://orcid.org/0000-0002-8267-5356)
Institutions
- Penn Center for AIDS Research (US)
- University of Pennsylvania Health System (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- JAMA Oncology
- Published
- 2025-11-13
- DOI
- https://doi.org/10.1001/jamaoncol.2025.4566
- Citations
- 1
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.01